- Report
- February 2024
- 113 Pages
Global
From €3500EUR$4,094USD£3,086GBP
- Report
- October 2023
- 146 Pages
Global
From €3231EUR$3,528USD£2,752GBP
€3801EUR$4,150USD£3,238GBP
- Report
- January 2025
- 132 Pages
Global
From €870EUR$950USD£741GBP
- Report
- September 2024
- 220 Pages
Global
From €1702EUR$1,859USD£1,450GBP
€2432EUR$2,655USD£2,071GBP
- Report
- July 2024
- 260 Pages
Global
From €1702EUR$1,859USD£1,450GBP
€2432EUR$2,655USD£2,071GBP
- Report
- May 2022
- 210 Pages
Global
From €2216EUR$2,419USD£1,887GBP
€3165EUR$3,456USD£2,696GBP
- Report
- January 2022
- 220 Pages
Global
From €2380EUR$2,598USD£2,027GBP
€3400EUR$3,712USD£2,896GBP
- Book
- July 2022
- 880 Pages
The Drug Eluting Balloon (DEB) market is a subset of the medical device industry. DEBs are used to treat peripheral artery disease (PAD) and coronary artery disease (CAD). They are designed to deliver a drug directly to the site of the blockage, allowing for improved efficacy and reduced side effects. DEBs are typically composed of a balloon catheter with a drug-eluting coating. The drug is released when the balloon is inflated, allowing for targeted delivery of the drug to the affected area.
DEBs have been shown to be effective in treating PAD and CAD, and are increasingly being used in clinical practice. They offer a minimally invasive alternative to traditional treatments such as stenting and bypass surgery.
Some companies in the DEB market include Medtronic, Boston Scientific, Abbott, and B. Braun. Show Less Read more
